{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:56:55Z","timestamp":1761897415890,"version":"3.40.5"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Although new multiple myeloma (MM) therapies are effective in alleviating some disease\u2010associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health\u2010related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalidomide\u2010bortezomib\u2010dexamethasone [RVd (<jats:italic>n<\/jats:italic>\u00a0=\u00a0445)], bortezomib\u2010melphalan\u2010prednisone [VMP (<jats:italic>n<\/jats:italic>\u00a0=\u00a077)] and Vd or VMP (<jats:italic>n<\/jats:italic>\u00a0=\u00a0588) in patients with newly diagnosed MM (NDMM) from the Connect<jats:sup>\u00ae<\/jats:sup> MM Registry, a large, USA, multicentre, prospective observational cohort study. Functional Assessment of Cancer Therapy\u2010Multiple Myeloma subscale, EuroQol\u20105D overall score and Bone Pain Inventory HRQoL scores were significantly improved with RVd <jats:italic>versus<\/jats:italic> Vd\/VMP. Serious adverse event rates were similar in all groups. Treatment with RVd maintained HRQoL in this real\u2010world, largely community\u2010based population of patients with NDMM.<\/jats:p>","DOI":"10.1111\/bjh.17131","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T11:08:33Z","timestamp":1603969713000},"page":"93-100","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of initial treatment on health\u2010related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect<sup>\u00ae<\/sup> MM Registry"],"prefix":"10.1111","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1491-2548","authenticated-orcid":false,"given":"Rafat","family":"Abonour","sequence":"first","affiliation":[{"name":"Indiana University Indianapolis IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-1518","authenticated-orcid":false,"given":"Robert M.","family":"Rifkin","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Centers US Oncology Denver CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[{"name":"Duke University Medical Center Durham NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Toomey","sequence":"additional","affiliation":[{"name":"Steeplechase Cancer Center Somerville NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian G. M.","family":"Durie","sequence":"additional","affiliation":[{"name":"Cedars\u2010Sinai Medical Center Los Angeles CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Hardin","sequence":"additional","affiliation":[{"name":"University of South Carolina Columbia SC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4208-2353","authenticated-orcid":false,"given":"Howard R.","family":"Terebelo","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute Southfield MI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit","family":"Narang","sequence":"additional","affiliation":[{"name":"US Oncology Research Columbia MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8111","authenticated-orcid":false,"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":"Mayo Clinic Jacksonville FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Omel","sequence":"additional","affiliation":[{"name":"Myeloma Research Advocate\/Advisor Grand Island NE USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankar","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amani","family":"Kitali","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Wagner","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine Winston\u2010Salem NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the CONNECT MM Registry Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0902-4441.2003.00195.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01250.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14058"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.06.019"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30051-6"},{"key":"e_1_2_7_7_1","unstructured":"MikhaelJ IsmailaN CheungMC CostelloC DhodapkarMV KumarS et al.Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. J Clin Oncol. 2019;37:1228\u201363."},{"key":"e_1_2_7_8_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Multiple Myeloma vol 2.2020. \u00a9 National Comprehensive Cancer Network Inc.2019. All rights reserved. Accessed [March 10 2020]. To view the most recent and complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2018-99-117003","article-title":"Longer Term Follow up of the \u00c2 Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)","volume":"132","author":"Durie BG","year":"2018","journal-title":"Blood"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_238527"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.7618"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.12.002"},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","unstructured":"JagannathS AbonourR DurieBG GasparettoC HardinJW NarangM et al.Heterogeneity of second\u2010line treatment for patients with multiple myeloma in the Connect MM Registry (2010\u20132016). Clin Lymphoma Myeloma Leuk.2018;18:480\u2013485.e3.","DOI":"10.1016\/j.clml.2018.04.007"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018017186"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3446-y"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0391"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.291"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.03.027"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphys.2015.07.001"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.9"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1179\/2042618612Y.0000000001"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.08.016"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.247"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15261"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128000"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111477"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw606"},{"key":"e_1_2_7_30_1","first-page":"S139","article-title":"Association of health\u2010related quality of life (HRQOL) with bone disease in multiple myeloma","volume":"96","author":"Pashos CL","year":"2011","journal-title":"Haematologica"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.3828.3828"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.5070.5070"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.3150.3150"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17131","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.17131","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T11:27:01Z","timestamp":1693567621000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.17131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/bjh.17131"],"URL":"https:\/\/doi.org\/10.1111\/bjh.17131","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"2020-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}